China Reviews Essential Drug Pricing Model After GMP Violations From Multi-bid Winner
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - While China implements a centralized tender system for essential drugs nationwide, the government also faces strong pushback from industry, which is questioning whether the current tender model is purely price competitive at the expense of quality. Following a product quality issue from a traditional Chinese medicine company that won essential drug tenders in several provinces, China's regulatory authority may consider modifying its approach
You may also be interested in...
Anhui Model Suggests More Pricing Pressure From Chinese Drug Tenders
HONG KONG - Meetings with government officials involved with the tender process in China's Anhui province suggest that the impact of price cuts for essential drugs has been greater than expected, Morgan Stanley analysts say in a June 6 research report
Anhui Model Suggests More Pricing Pressure From Chinese Drug Tenders
HONG KONG - Meetings with government officials involved with the tender process in China's Anhui province suggest that the impact of price cuts for essential drugs has been greater than expected, Morgan Stanley analysts say in a June 6 research report
In Brief
CDER reorganizes for global compliance